PRESS RELEASE
DNAnexus Named 2023 Company of the Year for Global Precision Medicine Informatics Industry
Frost & Sullivan recognizes the company for its ongoing commitment to empowering customers to derive insights from large-scale genomics, multi-omics, and clinical datasets
MOUNTAIN VIEW, Calif. — June 08, 2023 — DNAnexus Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced it was named the 2023 Company of the Year for the Global Precision Medicine Informatics Industry by Frost & Sullivan. DNAnexus was selected for its ability to provide a comprehensive cloud environment and tools to drive biological insights and advance precision medicine.
Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. The Company of the Year Award is presented to the organization that demonstrates excellence in growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.
“DNAnexus’ innovative bioinformatics solutions enable customers to solve complex genomics research and clinical pipeline challenges,” said Surbhi Gupta, Industry Analyst at Frost & Sullivan. “Frost & Sullivan believes the company is well-positioned to drive the precision medicine informatics space into its next growth phase, capturing market share and sustaining its leadership in the coming years.”
“We are honored to receive Frost & Sullivan’s Company of the Year Award,” said Richard Daly, CEO at DNAnexus. “DNAnexus continues to be the trusted precision health platform of choice for clinical diagnostics, biopharmaceuticals, and the world’s largest biomedical research programs. We are proud to play a role in transformational projects that are empowering researchers to accelerate the era of precision medicine.”
Today, DNAnexus has more than 12,000 users across 48 countries and actively manages and supports more than 80 petabytes of complex proteomic, genomic, multi-omic, and clinical datasets on behalf of a growing network of collaborators. The company provides a comprehensive cloud platform designed to meet the most rigorous standards for quality, security, privacy, and safety. The company was also recently included in Fast Company’s list of 10 Most Innovative Biotech Companies of 2023.
About DNAnexus
DNAnexus is a leading provider of secure, scalable, and intuitive biomedical data analysis software and bioinformatics applications for the life sciences and healthcare communities. The company actively manages and supports more than 80 petabytes of complex genomic, multi-omic, and clinical datasets on behalf of a growing network of collaborations with large-scale biobanks, as well as leading pharmaceutical, clinical diagnostic, academic research, and government organizations. Scientists across 48 countries are now using the highly collaborative, cloud-based, end-to-end platform to gain data-driven insights that can advance scientific discovery, accelerate precision medicine, and improve patient care. For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus.
Media Contact
Andrew Noble
415-722-2129
andrew@bioscribe.com